Core Insights - Arcutis Biotherapeutics, Inc. has released findings from a nationwide survey on patient perceptions regarding the use of topical steroids for chronic inflammatory skin diseases, highlighting a significant focus on reactive treatment rather than proactive management strategies [1][2][3] Group 1: Survey Findings - The survey involved 1,000 adults and 500 parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, revealing that most treatment plans are reactive, aimed at managing flare-ups rather than preventing them [3][5] - Concerns about the side effects of topical steroids are prevalent, with nearly 9 in 10 respondents expressing worry about potential short- or long-term effects [5][6] - A significant portion of adults (72%) and children (80%) reported experiencing uncontrolled disease at least once a month, indicating a high frequency of flare-ups [6] Group 2: Emotional and Social Impact - The emotional and mental burden of living with these conditions is substantial, with many adults and children experiencing discomfort, frustration, and anxiety when their skin condition is uncontrolled [6][10] - The survey indicates that nearly half of adults (47%) have avoided social interactions due to their condition, and over half of children have missed school or social activities [6][7] - Even when symptoms are managed, a majority still feel self-conscious and anxious about potential future flare-ups, with only 20% of adults and 19% of parents feeling completely confident in their treatment plans [10] Group 3: Industry Implications - The findings suggest a critical opportunity for the dermatology community to shift towards more proactive disease management strategies, moving away from the traditional episodic care model [9] - There is a growing consensus among dermatology professionals regarding the risks associated with long-term steroid use, emphasizing the need for alternative treatment options that provide sustained relief [9] - Arcutis Biotherapeutics aims to address these challenges by developing innovative therapies that meet the needs of patients with chronic inflammatory skin diseases [15]